Malignant Neoplasms – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Malignant Neoplasms – Drugs In Development, 2024 report and make more profitable business decisions.
A tumor is a mass comprising atypical neoplastic cells, frequently exhibiting pleomorphism and the capability to invade surrounding tissues. Malignant neoplasms possess the characteristic of metastasizing to distant anatomical sites and may recur even after surgical excision. Among the most prevalent types of malignant neoplasms are carcinomas, which arise from epithelial tissues, Hodgkin and non-Hodgkin lymphomas originating in the lymphatic system, leukemias affecting blood and bone marrow, melanomas arising from pigment-producing cells, and sarcomas affecting connective tissues. These diverse malignancies underline the complexity of cancer pathology, with each type requiring specific diagnostic and therapeutic approaches for effective management.
The Malignant Neoplasms drugs in development market research report provide comprehensive information on the therapeutics under development for Malignant Neoplasms, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Neoplasms and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Malignant Neoplasms | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 31 molecules, with 25 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Malignant Neoplasms therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Malignant Neoplasms pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Malignant Neoplasms treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
BiocadBiosyngen Pte Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Clover Biopharmaceuticals Ltd
DEKK-TEC Inc
G&E Herbal Biotechnology Co.
Ltd.
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Pacific Meinuoke Bio-Pharmarceutical Co Ltd
Johnson & Johnson
Kyowa Kirin Co Ltd
N1 Life Inc
Peg-Bio BioPharma Co Ltd
PharmaCyte Biotech Inc
Promomed Rus
Providence Health & Services
R-Pharm
Sanofi
Sathgen Biotech
Seta Clinic Group
Shanghai Sunway Biotech Co Ltd
Shenzhen Maiwei Biotech Co Ltd
Shionogi & Co Ltd
UCLAs Jonsson Comprehensive Cancer Center
University of California Los Angeles
Vivesto AB
Wuhan Binhui Biopharmaceutical Co Ltd
Wuhan YZY Biopharma Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Malignant Neoplasms reports